【4/18更新】CiNii ArticlesのCiNii Researchへの統合について

耳鼻咽喉科領域感染症に対するgatifloxacinの基礎的・臨床的検討

書誌事項

タイトル別名
  • Pharmacokinetic and clinical studies of gatifloxacin on otorhinolaryngological infections

この論文をさがす

抄録

Pharmacokinetic and clinical studies were carried out with gatifloxacin (GFLX) in otorhinolaryngological infections.The results were as follows:<BR>1. The concentration of GFLX in the mucous membrane of the middle ear was 2.68-3.64μEg/g, in the mucous membrane of paranasal sinuses was 0.30-2.49μEg/g, and in the tonsils, 0.06-3.12μg/g.<BR>2. Clinical efficacy rates were 77.8%(28/36) in otitis media, 96.4%(27/28) in paranasal sinusitis, and 81.8%(18/22) in tonsillitis.Overall clinical efficacy was assessed as excellent in 48 cases, good in 33, fair in 10 and poor in 5, the efficacy rate being 84.4%(81/96).<BR>Bacteriological elimination rates were 85.7%(60/70) for Gram-positive bacteria and 88.9%(24/27) for Gram-negative bacteria. The rate for anaerobes was 100%(11/11).<BR>Side effects were observed in eight of 138 cases (5.8 %), but they were slight.<BR>Abnormal laboratory findings were recorded in 2 cases (2.1 %). All were mild in degree.<BR>From the above results, we conclude that GFLX is a useful drug for the treatment of otorhinolaryngological infections.

収録刊行物

被引用文献 (7)*注記

もっと見る

参考文献 (9)*注記

もっと見る

関連論文

もっと見る

関連研究データ

もっと見る

関連図書・雑誌

もっと見る

関連博士論文

もっと見る

関連プロジェクト

もっと見る

関連その他成果物

もっと見る

詳細情報

問題の指摘

ページトップへ